Discontinuation of statins in routine care settings, A cohort study

Annals of Internal Medicine

Volumn 158, Issue 7, 2013, Pages 526-534

  Zhang, Huabing ^a   Plutzky, Jorge ^b   Skentzos, Stephen ^c   Morrison, Fritha ^d   Mar, Perry ^e   Shubina, Maria ^f   Turchin, Alexander ^f  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c not available   (United States)

^d TULANE UNIVERSITY   (United States)

^e Partners Information Systems   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMPUTER PROGRAM; CONNECTIVE TISSUE DISEASE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEMORY DISORDER; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; TREATMENT DURATION;

EID: 84875727583     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-7-201304020-00004     Document Type: Article

References (46)

1. Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholes-terolemia, treatment and control among United States adults. Int J Cardiol. 2010;140:226-35.
2. Zaninotto P, Head J, Stamatakis E, Wardle H, Mindell J. Trends in obesity among adults in England from 1993 to 2004 by age and social class and projec-tions of prevalence to 2012. J Epidemiol Community Health. 2009;63:140-6.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum choles-terol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor In-tervention Trial (MRFIT). JAMA. 1986;256:2823-8.
4. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuv-astatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-60.
5. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011:CD004816.
6. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383-9.
7. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-9.
9. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med. 1997;336:153-62.
10. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380: 581-90.
11. Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002;287:337-44.
12. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279:1458-62.
13. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary pre-vention populations. J Gen Intern Med. 2004;19:638-45.
14. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288:455-61.
15. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288: 462-7.
16. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) In-vestigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation. 2002;105:1446-52.
17. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial in-farction: a six year follow up study. Heart. 2002;88:229-33.
18. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.
19. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, et al. Medication nonadherence is associated with a broad range of adverse out-comes in patients with coronary artery disease. Am Heart J. 2008;155:772-9.
20. McGinnis B, Olson KL, Magid D, Bayliss E, Korner EJ, Brand DW, et al. Factors related to adherence to statin therapy. Ann Pharmacother. 2007;41:1805-11.
21. Garavalia L, Garavalia B, Spertus JA, Decker C. Exploring patients' reasons for discontinuance of heart medications. J Cardiovasc Nurs. 2009;24:371-9.
22. Fung V, Sinclair F, Wang H, Dailey D, Hsu J, Shaber R. Patients' perspec-tives on nonadherence to statin therapy: a focus-group study. Perm J. 2010;14: 4-10.
23. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781-90.
24. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-97.
25. Skentzos S, Shubina M, Plutzky J, Turchin A. Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository. AMIA Annu Symp Proc. 2011;2011:1270-9.
26. Brown AS, Bakker-Arkema RG, Yellen L, Henley RW Jr, Guthrie R, Campbell CF, et al. Treating patients with documented atherosclerosis to Na-tional Cholesterol Education Program-recommended low-density lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol. 1998;32:665-72.
27. Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontin-uation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17:3669-89.
28. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14.
29. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Preva-lence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23:1182-6.
30. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a com-mon dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393-403.
31. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365:2250-1.
32. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology. ACC/AHA/NHLBI Clinical Ad-visory on the Use and Safety of Statins. Circulation. 2002;106:1024-8.
33. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C-60C.
34. Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an un-derestimated risk? [Editorial]. Curr Med Res Opin. 2008;24:3059-62.
35. National Cholesterol Education Program (NCEP) Expert Panel on Detec-tion, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Pro-gram (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
36. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology. ACC/AHA/NHLBI Clinical Ad-visory on the Use and Safety of Statins. Stroke. 2002;33:2337-41.
37. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 pa-tients with statin-associated myopathy. Arch Intern Med. 2005;165:2671-6.
38. Glueck CJ, Aregawi D, Agloria M, Khalil Q, Winiarska M, Munjal J, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with non-statin lipid-lowering therapies. Clin Ther. 2006;28:933-42.
39. Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother. 2008;42:341-6.
40. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol. 2008;101:483-5.
41. Ruisinger JF, Backes JM, Gibson CA, Moriarty PM. Once-a-week rosuvas-tatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol. 2009;103:393-4.
42. Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes. 2011;4:155-66.
43. Blaier O, Lishner M, Elis A. Managing statin-induced muscle toxicity in a lipid clinic. J Clin Pharm Ther. 2011;36:336-41.
44. Blumenthal D, Tavenner M. The "meaningful use" regulation for electronic health records. N Engl J Med. 2010;363:501-4.
45. Hripcsak G, Friedman C, Alderson PO, DuMouchel W, Johnson SB, Clayton PD. Unlocking clinical data from narrative reports: a study of natural language processing. Ann Intern Med. 1995;122:681-8.
46. Brown SH, Elkin PL, Rosenbloom ST, Fielstein E, Speroff T. eQuality for all: Extending automated quality measurement of free text clinical narratives. AMIA Annu Symp Proc. 2008:71-5.